Well it looks like Bota doesn't want to diversify out of self limiting respiratory diseases. Which means there will always be debate about the cost benefit of shaving 1 day off symptoms of influenza or rhinovirus or RSV.
There's still debate whether Medimmune's RSV drug is cost effective & efficacious but it didn't stop it earning $1 billion per annum in a small cohort of the population not long ago.
My 2c.
BTA Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
